| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | $35.7 | $5.93B | N/A |
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
http://www.zacks.com/stock/news/282370/vivus-vvus-q3-loss-narrows-qsymia-falters-shares-down?cid=CS-ZC-FT-282370
Nov 09, 2017 - VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
0
Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y
http://www.zacks.com/stock/news/290129/dr-reddys-rdy-q3-earnings-fall-revenues-improve-y-y?cid=CS-ZC-FT-290129
Jan 25, 2018 - Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
0
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
http://www.zacks.com/stock/news/304716/dr-reddys-rdy-q4-earnings-fall-revenues-decline-y-y?cid=CS-ZC-FT-304716
May 23, 2018 - Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
0
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
http://www.zacks.com/stock/news/325877/dr-reddys-sells-antibiotic-production-hub-to-uae-drugmaker?cid=CS-ZC-FT-325877
Oct 02, 2018 - Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
0
J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment
http://www.zacks.com/stock/news/338281/jj-gets-positive-chmp-opinion-for-prostate-cancer-treatment?cid=CS-ZC-FT-338281
Nov 19, 2018 - Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
0
Generic Industry on Path to Recovery: 3 Hot Picks for 2019
http://www.zacks.com/stock/news/345019/generic-industry-on-path-to-recovery-3-hot-picks-for-2019?cid=CS-ZC-FT-345019
Dec 28, 2018 - The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.
0
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar
http://www.zacks.com/stock/news/345603/teva-teva-ends-dispute-with-amgen-over-generic-sensipar?cid=CS-ZC-FT-345603
Jan 03, 2019 - Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
0
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
http://www.zacks.com/stock/news/346828/akorn-akrx-gets-fda-warning-letter-for-illinois-facility?cid=CS-ZC-FT-346828
Jan 10, 2019 - Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
0
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
http://www.zacks.com/stock/news/365966/falling-earnings-estimates-signal-weakness-ahead-for-mylan-myl?cid=CS-ZC-FT-365966
Mar 28, 2019 - Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
0
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat
http://www.zacks.com/stock/news/415513/dr-reddys-rdy-earnings-rise-in-q4-revenues-beat?cid=CS-ZC-FT-415513
May 17, 2019 - Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.
0